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Introduction: Major problem for diabetic patients represents dam-
age of blood vessels and the oxidative stress of the brain cells due to 
increased concentration of free radicals and poor nutrition of brain 
cells. Gliclazide has antioxidative properties and poor blood brain 
barrier (BBB) penetration. Bile acids are known for their hypogly-
cemic effect and as prooters of drug penetration across biological 
membranes.
Aim: The aim of this study is to investigate whether the bile acid 
(deoxycholic acid) can change the permeation of gliclazide, through 
the blood brain barrier of a rat model type-1 diabetes.
Patients (or Materials) and Methods: Twenty-four male Wistar rats 
were randomly allocated to 4 groups, of which 2 were given alloxan 
intraperitoneally (100 mg/kg) to induce diabetes. One diabetic group 
and 1 healthy group were given a bolus gliclazide intra-arterially (20 
mg/kg), while the other 2 groups apart from gliclazide got deoxy-
cholic acid (4 mg/kg) subcutaneously. Blood samples were collected 
30, 60, 150, and 240 seconds after dose, brain tissues were immedi-
ately excised, and blood glucose and gliclazide concentrations were 
measured.
Results: Penetration of gliclazide in groups without deoxycholic 
acid pretreatment was increased in diabetic animals compared with 
healthy animals. Also in both, healthy and diabetic animals, deoxy-
cholic acid increased the permeation of gliclazide through that in 
BBB. Deoxycholic acid pretreatment also changed the pattern of 
blood glucose level increase after gliclazide application in diabetic 
as well as in healthy animals.
Conclusion: Deoxycholic acid promotes gliclazide penetration across 
BBB in diabetic and in healthy animals. In addition, deoxycholic 
acid alters some pharmacokinetic properties of gliclazide in both 
healthy and diabetic rats. Thus, deoxycholic acid should be more 
investigated in the treatment of diabetes mellitus and as permea-
tion promoter of lipophilic molecules through BBB as well as other 
biological membranes.
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Introduction: Paracetamol (APAP) is recommended as the initial 
pharmacologic treatment of choice for the management of osteoar-
thritis (OA). However, inadequate compliance with the prescribed 
regimen can lead to reduced efficacy. This may in turn prompt 
patients to switch to other analgesics with increased safety risks. 
Panadol 1 g sustained release (P12) tablet is a twice-daily sustained 
released formulation that provides 4 g of paracetamol per day that 
could dramatically enhance patient’s compliance and reduce the pos-
sibility of switching to less well-tolerated drugs. The main objective of 
this investigation was to evaluate the maximum paracetamol concen-
tration in plasma (Cmax) after a twice-daily dosing (BID) regimen with 
P12 compared with the currently marketed immediate-release (IR) 
formulation. In addition, we apply pharmacokinetic-pharmacody-
namic concepts to assess the time that APAP levels remain above the 
minimum effective concentration (MEC) and evaluate the potential 
impact of differences in exposure between the 2 formulations on the 
risk of hepatotoxicity in osteoarthritis patients.
Patients (or Materials) and Methods: A population PK model was 
developed using data from 3 Phase I studies and 1 study in patients 
with type 2 diabetes to explore the effects of demographic covariates. 
Using the nomogram line as reference to assess the risk of APAP-
induced hepatotoxicity, different dosing scenarios were simulated 
taking into account the effects of age, sex, and body weight. Peak 
concentrations (Cmax) were used as measure of interest to assess the 
probability of liver toxicity. APAP concentrations were assumed to 
be the primary driver of toxicity.
Results: Our results show that there is no difference in the risk 
of hepatotoxicity between the regimens when APAP is taken at 
therapeutic doses or after an unintentional overdose of 4 tablets. 
After an unintentional overdose with 10 tablets, hepatotoxicity 
is predicted for 1 of 10,000 patients taking the IR formulation 
under fasted conditions and for none of the patients taking the 
P12 formulation. After overdose with 10 tablets, patients with 
low body weight are likely to exceed the toxic threshold by no 
more than 0% to 0.94% for the IR and by 0.04% to 0.15% for 
P12 formulation.
Conclusion: In conclusion, the risk of hepatotoxicity after BID dos-
ing appears to be similar to the standard regimen. Our analysis also 
reveals that the proportion of patients who stay above the MEC is 
higher for P12 when APAP is taken under fasting conditions. These 
results illustrate the relevance of clinical trial simulations before the 
implementation of a clinical trial protocol. Our approach illustrates 
what should be considered best-practice in the evaluation of drug 
safety in late clinical development.
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Introduction: In the current situation of worldwide spreading of mul-
tidrug-resistant A baumannii and only a few effective antimicrobial 
agents currently available, sulbactam is a potentially useful alterna-
tive treatment option for this pathogen. This agent is characterized by 
time-dependent antimicrobial activity and the exposure time during 
which the free drug concentration remains above the MIC (T> MIC) 
is the pharmacokinetic/pharmacodynamic (PK/PD) index that best 
correlates with efficacy.
Objectives: The aims of the study were to: (1) reveal a population 
pharmacokinetic (PK) model to describe the disposition of sulbactam; 
and (2) assess the efficacy of various dosage regimens of sulbactam 
in achieving the probability of target attainment (PTA) of this agent 
over a range of MICs.
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Patients (or Materials) and Methods: The study was conducted in 12 
healthy volunteers. Each patient received a 1-g single dose intrave-
nously of sulbactam, after which PK studies were carried out, using 
a Monte Carlo simulation to determine the probability of attaining 
a specific pharmacodynamic target.
Results: The population PKs of sulbactam were; k12 = 0.637 (2.003) 
h-1, k21 = 0.663 (1.736) h-1, k13 = 8.626 (2.035) h-1, k31 = 5.424 
(2.058) h-1 ke = 3.223 (1.380) h-1, CL = 11.903 (1.978) L/h and V 
= 3.693 (1.434) L. The PTAs for selected regimens over a range of 
MICs were as follows:
Conclusion: The high PTA (≥ 90%) achieving 40% T> MIC for an 
MIC of 8 mg/L was observed when sulbactam was administered by a 
4-hour infusion of 3 g q8h, which would be an alternative treatment 
option for less-susceptible pathogens.
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Introduction: Piperine is the main pungent alkaloid present in the 
fruits of black pepper (Piper nigrum) and long pepper (Piper longum).
In traditional medicine, black pepper has been used as an analgesic 
and anti-inflammatory agent and in the treatment of epilepsy and 
snake venom poisoning. Piperine also has been reported as an inhibi-
tor against several cytochrome P-450–mediated pathways and Phase 
II metabolism as well as P-glycoprotein. This study was carried out 
to investigate the effect of piprine on the pharmacokinetics of dom-
peridone after acute and chronic administration in rats.
Patients (or Materials) and Methods: Animals received a single dose 
of domperidone (20 mg/kg, p.o.) alone or together with piperine (60 
mg/kg, p.o.). Similarly, the same doses of domperidone alone or when 
it was given together with piperine were administered to rats chroni-
cally for 5 days. Plasma samples were collected at 0.25, 0.5, 1.0, 2.0, 
3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 hours after drug administration. 
The concentrations of domperidone in the plasma were measured 
using an HPLC method.
Results: The concomitant administration of piperine with dom-
peridone acutely or chronically resulted in a significant (P < 0.05) 
increase in the maximum plasma concentration (Cmax), the mean 
area under the plasma concentration–time curve (AUC), and the elim-
ination half-life (t½) of domperidone compared with those obtained 
for domperidone alone.
Conclusion: The concurrent administration of piprine with dom-
peridone to rats produced a significant increase in the plasma levels 
of the latter. However, further studies are needed to determine the 
possible mechanism(s) involved in this pharmacokinetic interaction.
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Introduction: Introducing of a standard drug monitoring for digoxin, 
a digitalis glycoside using in heart failure, considerably reduce the 
incidences of digoxin toxicity. The need for measurement of digoxin 
concentrations and knowledge about bioavailability of the given 
preparation arise from the low therapeutic index of digoxin and 
its concentration-dependent toxicity. The recommended therapeutic 
range (1.0–2.5 nmol/L) reflects significant increase in the risk of toxic-
ity that occurs with serum concentrations over 2.6 nmol/L. Choosing 
a proper analytical method for digoxin bioavailability evaluation is 
essential due to digoxin-like immunologic factor (DLIF) and others 
interfering substances that overestimate serum digoxin concentration 
which may be a significant clinical problem.
Patients (or Materials) and Methods: The study was performed on 
24 healthy volunteers in accordance with GCP and legal require-
ments. Digoxin tablets were administered as a single dose of 0.5 mg. 
Pharmacokinetic profiles were plotted up to 60 hours after dosing. 
Determination of digoxin concentration in serum samples was per-
formed by immunoenzymatic method by using the Emit® 2000 Digoxin 
Assay (Siemens Healthcare Diagnostics). EMIT is a homogeneous 
enzyme immunoassay intended for use in the quantitative analysis of 
digoxin in human serum or plasma. The method was fully validated 
according to the international guidelines. Original solutions of digoxin 
were used as calibration standards. Lower limit of quantification was 
set at the concentration of 0.1 ng/mL that is sufficient for human phar-
macokinetic evaluation. Standard pharmacokinetic and bioavailabil-
ity parameters in single-dose regiment (AUCt, AUCinf, Cmax, Tmax, 
MRT, t1/2) were calculated by a noncompartmental method.
Results: Study results, including t1/2 and other bioavailability 
parameters, were in agreement with the reference data. Mean AUCinf 
was 33.42 (10.13) ng*h/mL, while AUCt was 23.93 (6.70) ng*h/
mL. Cmax was observed as 3.24 (0.77) ng/mL but occurred at dif-
ferent Tmax (range, 0.5–2.5 hours). The intersubject variability was 
similar in case of AUC and Cmax (range, 23.80%–30.31%). The 
high variability of Tmax was observed (49.33%). Cmax exceed the 
recommended therapeutic ranges in most cases due to administration 
of a high dose of the tested drug. Digoxin tablets elimination half-life 
in healthy volunteers, even after single dose administration is high 
(32.78 [6.48] hours) as well as MRT (44.14 [8.34] hours).
Conclusion: The study results have confirmed that the EMIT method 
was appropriate for assessment digoxin bioavailability and can be 
used not only as reliable screening test but also in bioavailability and 
bioequivalence evaluation.
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Dosage regimen MIC (mg/L) PTA of T> MIC
20%
40% 30%
1 g q8h (1/2/3/4 h infusion) 1 0.17/0.99/0.99/0.99
2 0.00/0.21/0.99/0.99
4 0.00/0.00/0.44/0.99
2 g q8h (1/2/3/4 h infusion) 1 0.04/0.99/0.99/0.97
2 0.00/0.06/0.99/0.97
4 0.00/0.00/0.20/0.97
3 g q8h (1/2/3/4 h infusion) 4 0.06/0.96/0.88/0.73
8 0.00/0.00/0.87/0.73
4 g q8h (1/2/3/4 h infusion) 4 0.00/0.00/0.02/0.72
8 0.43/1.00/0.99/0.99
3/6/9/12 g q24h (continuous 
infusion)
4 0.11/0.46/0.99/0.99 
0.02/0.07/0.66/0.99 
0.17/0.99/0.99/0.99 
0.00/0.21/0.99/0.99
